HRP20240309T1 - Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid - Google Patents
Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid Download PDFInfo
- Publication number
- HRP20240309T1 HRP20240309T1 HRP20240309TT HRP20240309T HRP20240309T1 HR P20240309 T1 HRP20240309 T1 HR P20240309T1 HR P20240309T T HRP20240309T T HR P20240309TT HR P20240309 T HRP20240309 T HR P20240309T HR P20240309 T1 HRP20240309 T1 HR P20240309T1
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- intended
- linezolid
- pharmaceutical preparation
- accordance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562241280P | 2015-10-14 | 2015-10-14 | |
| PCT/US2016/055414 WO2017066053A1 (en) | 2015-10-14 | 2016-10-05 | Combination antibacterial composition and short-course antibacterial regimen |
| EP16855973.0A EP3362068B1 (en) | 2015-10-14 | 2016-10-05 | Combination antibacterial composition and short-course antibacterial regimen comprising linezolid, bedaquiline and pretomanid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240309T1 true HRP20240309T1 (hr) | 2024-05-10 |
Family
ID=58518568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240309TT HRP20240309T1 (hr) | 2015-10-14 | 2016-10-05 | Kombinirani antibakterijski pripravak i kratkotrajni antibakterijski režim, koji uključuje linezolid, bedakvilin i pretomanid |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20180280401A1 (enExample) |
| EP (2) | EP4324824A3 (enExample) |
| JP (5) | JP6845233B2 (enExample) |
| KR (2) | KR102706436B1 (enExample) |
| CN (2) | CN114796231A (enExample) |
| AU (3) | AU2016338637A1 (enExample) |
| BR (1) | BR112018007625A2 (enExample) |
| CA (1) | CA3001309C (enExample) |
| EA (1) | EA201890614A1 (enExample) |
| ES (1) | ES2972618T3 (enExample) |
| HK (1) | HK1254620A1 (enExample) |
| HR (1) | HRP20240309T1 (enExample) |
| PL (1) | PL3362068T3 (enExample) |
| WO (1) | WO2017066053A1 (enExample) |
| ZA (1) | ZA201802236B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016338637A1 (en) * | 2015-10-14 | 2018-04-26 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and short-course antibacterial regimen |
| AU2018298855B2 (en) | 2017-07-14 | 2024-07-18 | Janssen Pharmaceutica Nv | Long-acting formulations |
| CN109387594B (zh) * | 2017-08-08 | 2021-01-19 | 武汉武药科技有限公司 | 一种分离和分析贝达喹啉光学异构体的方法 |
| AU2020316989B2 (en) * | 2019-07-19 | 2024-02-15 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid compositions |
| EP4164626A4 (en) * | 2020-06-15 | 2024-07-03 | Mylan Laboratories Ltd. | Combination antibacterial composition and method for antibacterial therapy |
| EP4164645A4 (en) * | 2020-06-15 | 2024-07-10 | The Global Alliance for TB Drug Development, Inc. | COMBINED ANTIBACTERIAL COMPOSITION AND ANTIBACTERIAL THERAPY METHOD |
| GB202009684D0 (en) * | 2020-06-26 | 2020-08-12 | Viiv Healthcare Co | Formulations |
| CA3206024A1 (en) * | 2021-02-01 | 2022-08-04 | The Global Alliance For Tb Drug Development, Inc. | Pretomanid amorphous form |
| JP2026525955A (ja) | 2023-07-18 | 2026-08-04 | ヤンセン ファーマシューティカ エヌ．ベー． | ベダキリン、プレトマニド又はデラマニド、及びシトクロムｂｃ１阻害剤を含む、少なくとも三種の抗生物質の組み合わせ製品、並びにマイコバクテリア感染症の治療におけるそれらの使用 |
| CN117137918A (zh) * | 2023-09-28 | 2023-12-01 | 深圳国家感染性疾病临床医学研究中心 | 一种药物组合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7889101B2 (en) * | 2008-04-14 | 2011-02-15 | Alpine Electronics, Inc | Method and apparatus for generating location based reminder message for navigation system |
| NZ591169A (en) * | 2008-09-03 | 2012-12-21 | Pfizer | Combination therapy for tuberculosis |
| WO2011139832A2 (en) * | 2010-04-28 | 2011-11-10 | Rib-X Pharmaceuticals, Inc. | Method for treating mycobacterial infections |
| AU2016338637A1 (en) | 2015-10-14 | 2018-04-26 | The Global Alliance For Tb Drug Development, Inc. | Combination antibacterial composition and short-course antibacterial regimen |
-
2016
- 2016-10-05 AU AU2016338637A patent/AU2016338637A1/en not_active Abandoned
- 2016-10-05 HK HK18113586.3A patent/HK1254620A1/zh unknown
- 2016-10-05 KR KR1020187013661A patent/KR102706436B1/ko active Active
- 2016-10-05 EP EP23214018.6A patent/EP4324824A3/en active Pending
- 2016-10-05 WO PCT/US2016/055414 patent/WO2017066053A1/en not_active Ceased
- 2016-10-05 EA EA201890614A patent/EA201890614A1/ru unknown
- 2016-10-05 JP JP2018518950A patent/JP6845233B2/ja active Active
- 2016-10-05 EP EP16855973.0A patent/EP3362068B1/en active Active
- 2016-10-05 HR HRP20240309TT patent/HRP20240309T1/hr unknown
- 2016-10-05 CA CA3001309A patent/CA3001309C/en active Active
- 2016-10-05 US US15/765,310 patent/US20180280401A1/en active Pending
- 2016-10-05 CN CN202210425060.2A patent/CN114796231A/zh active Pending
- 2016-10-05 ES ES16855973T patent/ES2972618T3/es active Active
- 2016-10-05 KR KR1020247030236A patent/KR20240137128A/ko not_active Ceased
- 2016-10-05 BR BR112018007625A patent/BR112018007625A2/pt not_active Application Discontinuation
- 2016-10-05 CN CN201680073150.2A patent/CN108495631A/zh active Pending
- 2016-10-05 PL PL16855973.0T patent/PL3362068T3/pl unknown
-
2018
- 2018-04-05 ZA ZA2018/02236A patent/ZA201802236B/en unknown
-
2020
- 2020-04-09 US US16/843,946 patent/US20200237770A1/en not_active Abandoned
- 2020-11-27 JP JP2020196684A patent/JP7221922B2/ja active Active
-
2021
- 2021-10-28 AU AU2021258039A patent/AU2021258039B2/en active Active
-
2022
- 2022-04-07 JP JP2022063917A patent/JP2022082753A/ja active Pending
-
2023
- 2023-09-06 US US18/242,560 patent/US20230414625A1/en active Pending
-
2024
- 2024-03-07 JP JP2024034841A patent/JP2024053045A/ja active Pending
- 2024-05-07 AU AU2024203012A patent/AU2024203012B2/en active Active
- 2024-09-03 JP JP2024151159A patent/JP2024167369A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| PH12020550237A1 (en) | Methods for the administration of certain vmat2 inhibitors | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| FI3936130T3 (fi) | Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon | |
| JP2015057451A5 (enExample) | ||
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| HRP20251174T1 (hr) | Postupci za liječenje psorijatičnog artritisa uporabom il-17 antagonista | |
| EP4650370A3 (en) | Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient | |
| JP2015038135A5 (enExample) | ||
| MX2021016109A (es) | Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion. | |
| JP2018530578A5 (enExample) | ||
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| JP2016539156A5 (enExample) | ||
| JP2016532516A5 (enExample) | ||
| HRP20201632T1 (hr) | Režimi doziranja melflufena kod raka | |
| MX2018000546A (es) | Composiciones farmaceuticas que contienen celecoxib y tramadol. | |
| EA201890614A1 (ru) | Комбинированная антибактериальная композиция и короткий курс антибактериальной терапии | |
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| HRP20240166T1 (hr) | Postupak liječenja prader-willijevog sindroma | |
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| MY198553A (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| ZA202003904B (en) | Drug delivery system |